Blue Trust Inc. reduced its holdings in Fresenius Medical Care AG (NYSE:FMS – Free Report) by 55.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,734 shares of the company’s stock after selling 7,129 shares during the quarter. Blue Trust Inc.’s holdings in Fresenius Medical Care were worth $130,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in FMS. Allworth Financial LP boosted its holdings in Fresenius Medical Care by 53.1% in the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after acquiring an additional 581 shares during the last quarter. First Trust Direct Indexing L.P. grew its stake in Fresenius Medical Care by 9.7% during the third quarter. First Trust Direct Indexing L.P. now owns 22,901 shares of the company’s stock worth $488,000 after buying an additional 2,021 shares during the period. Crossmark Global Holdings Inc. grew its stake in Fresenius Medical Care by 60.4% during the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock worth $1,340,000 after buying an additional 23,692 shares during the period. Venturi Wealth Management LLC lifted its holdings in shares of Fresenius Medical Care by 1,045.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after acquiring an additional 4,800 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Fresenius Medical Care in the 3rd quarter valued at $420,000. 8.37% of the stock is currently owned by hedge funds and other institutional investors.
Fresenius Medical Care Stock Up 0.6 %
Shares of NYSE:FMS opened at $23.09 on Friday. The stock has a market capitalization of $13.55 billion, a price-to-earnings ratio of 19.08, a price-to-earnings-growth ratio of 0.77 and a beta of 0.93. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $25.25. The company’s fifty day moving average is $23.41 and its two-hundred day moving average is $21.66. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.
Analyst Ratings Changes
Fresenius Medical Care Profile
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
- Five stocks we like better than Fresenius Medical Care
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Energy and Oil Stocks Explained
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG (NYSE:FMS – Free Report).
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.